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ABSTRACT 16 
Amniotic membrane is widely used in the treatment of ocular surface disorders in 17 
human and veterinary patients.  Preservation and storage of amnion has proven 18 
challenging, prompting the development of new preservation techniques. Omnigen®, 19 
a novel low-temperature vacuum-dehydrated amnion, is reported to possess 20 
enhanced structural properties and biochemical stability in vitro, but its clinical use in 21 
veterinary patients is not well-described.  This study aims to document and describe 22 
the varied use of Omnigen for the surgical treatment of corneal ulceration in cats and 23 
dogs. A total of 45 patients (46 eyes) were recruited from the clinical record system 24 
of the Royal Veterinary College (London) between January 2016 and December 25 
2017.  Brachycephalic breeds were over-represented (37/45; 82.2%).  Omnigen was 26 
used as a standalone graft in 5/46 (10.9%) eyes, as a supplementary graft in 29/46 27 
(63.0%) eyes and as a patch in 12/46 (26.1%) eyes.  Graft failure occurred in 10/46 28 
eyes (21.7%).  At final examination 43/46 eyes (93.5%) had healed and 31/33 eyes 29 
(93.9%) were visual.  This study demonstrates the successful use of Omnigen for the 30 
surgical treatment of corneal ulceration in cats and dogs. Further studies are needed 31 
to clarify its properties and benefits in the clinical field. 32 
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INTRODUCTION 35 
Corneal ulceration is a common ocular condition encountered in cats and dogs. It is 36 
widely accepted that simple, uncomplicated ulcerative lesions often respond to 37 
medical management, while complicated ulcers are likely to require surgical 38 
intervention.  This is particularly true in cases where the corneal defect is rapidly 39 
progressive, exhibits signs of keratomalacia or necrosis, invades deeper regions of 40 
the cornea, or perforates it entirely.   41 
 42 
Surgical grafting may be helpful in providing tectonic support, vascular supply and 43 
locally available beneficial factors to the cornea. Many graft types and techniques 44 
have been described in the veterinary literature, including autologous conjunctival 45 
grafts[1-6], autologous corneoconjunctival transposition[7-9] and 46 
homologous/heterologous fresh and frozen corneal transplants[10-15]. In addition, 47 
the use of various synthetic, processed and unadulterated biological grafts and 48 
patches has been reported, including equine renal capsule[16], equine 49 
pericardium[17,18], bovine pericardium[19] and acellular submucosa derived from 50 
porcine small intestinal submucosa[20-28] and urinary bladder[21,29-32].   51 
 52 
Amniotic membrane (AM) is one such grafting biomaterial which has garnered 53 
attention.  Amniotic membrane is the avascular inner layer of the foetal placental 54 
membrane and comprises three layers: an epithelial monolayer, a thick basement 55 
membrane and an avascular stromal matrix. It is reported to promote 56 
epithelisation[33-43], and possesses anti-inflammatory[44-47], anti-fibroblastic[48-57 
50], anti-angiogenic[44,51] and anti-microbial[52-55] properties. Additionally, it 58 
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exhibits immune-privilege (does not express HLA-A, B, or DR antigens) and hence is 59 
not rejected by the host immune system after transplantation[56-59].   60 
 61 
The use of AM in the treatment of human ocular surface disease was first reported 62 
by de Rötth in 1940[60]  who described the utilisation of AM in the repair of 63 
conjunctival defects in a small group of human patients. Although its use 64 
subsequently receded from the clinical field, AM enjoyed a resurgence in the 1990s. 65 
Since then, there has been increasing interest in the use of AM in the treatment of 66 
ocular surface disease in human and veterinary ophthalmology[49,61-86].  In 67 
addition to its use as a reconstructive grafting material, AM may also be used as a 68 
wound healing biological ‘bandage’ or ‘patch’. The decision as to whether AM is used 69 
as a graft or a patch in a specific case depends on the therapeutic aim.  If the AM is 70 
being used with the aim of providing a substrate on which the host epithelium can 71 
grow and stromal cells repopulate, the AM is trimmed to the size of the defect and 72 
placed epithelium side facing up (stroma facing recipient cornea); during the healing 73 
process, the AM should be incorporated into the cornea.  This is termed the ‘graft’ or 74 
‘inlay’ technique.  Alternatively, AM may be placed stromal side up (epithelium facing 75 
recipient cornea) as a removable ‘patch’ or ‘overlay’; this technique allows the 76 
epithelium to grow under the AM, which provides protection to the ocular surface, 77 
reduction of inflammation, reduction of pain and promotion of healing 78 
[46,77,80,82,83,87-90].  When used as a patch, the amnion is expected to slough 79 
from the ocular surface[91].  80 
 81 
Although the procurement of AM is relatively straightforward (usually collected via 82 
elective caesarean of human and veterinary patients), fresh AM is rarely used due to 83 
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its short shelf-life and, particularly in the human field, concerns about increased risk 84 
of disease transmission and post-operative complications[92]. Preservation of AM 85 
tissue and maintenance of its beneficial properties has proven challenging. 86 
Cryopreservation, lyophilisation (freeze-drying) and heat-drying are popular methods 87 
of AM preservation, but all three processes have been associated with inducing 88 
tissue fragility and/or loss of beneficial bioactive substances[92-98]. In addition, 89 
poorly standardised and validated preparation and storage methods have been 90 
known to  result in variable and unpredictable end products[92]. This prompted the 91 
development of a novel and standardised method of AM preparation, which aims to 92 
preserve the regenerative properties of fresh amnion while overcoming the 93 
limitations associated with fresh amnion and conventional preservation techniques. 94 
This is achieved via a unique, patented low-temperature vacuum-evaporation 95 
dehydration process (Tereo®; Nu-Vision Biotherapies Ltd.), which is reported to 96 
produce a preserved AM tissue with enhanced structural properties and biochemical 97 
stability (Omnigen®; Nu-Vision Biotherapies Ltd.). Specifically, Omnigen exhibits 98 
more sustained release of EGF and TGF-ß1 in vitro and less visible structural 99 
damage when compared to cryopreserved AM; more akin to fresh AM. In addition, 100 
increased wound closure rates were observed in an immortalised human corneal 101 
epithelial cell co-cultures with Omnigen compared to cryopreserved and fresh AM, 102 
possibly attributable to the optimised retention of wound-healing factors (EGF, HGF, 103 
PDGF and TGF- ß) in Omnigen[92,99]. The thickness of rehydrated Omnigen (mean 104 
69.78 µm) is comparable to fresh human amnion (mean 69.99 µm)[100].  105 
 106 
The clinical use of Omnigen was briefly discussed at recent veterinary 107 
ophthalmology conferences[101,102], and is sparsely described in human and 108 
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veterinary literature[103,104].  The purpose of the present study was to describe the 109 
varied clinical use of Omnigen for the surgical treatment of corneal ulceration in a 110 
group of canine and feline veterinary patients.  111 
 112 
 113 
MATERIALS & METHODS 114 
Data Collection  115 
This project was approved by the Royal Veterinary College Ethics & Welfare 116 
Committee on 13th February 2018 (Unique Reference Number SR2017-1296).  A 117 
VetCompass™ clinical record search was performed to identify case records 118 
including the word ‘amnion’ within the data silo of the Royal Veterinary College 119 
(RVC, London, U.K.) between January 2016 and December 2017. During this period 120 
Omnigen was the only form of AM available to the surgeons at the RVC. Surgery 121 
was performed by one of five different surgeons; all were either board-certified 122 
ophthalmologists or ophthalmology residents in training. Data collected for each 123 
patient included species, breed, brachycephalic status, age, gender, eye, diagnosis, 124 
complicating factors, cytological/microbiological findings, concurrent ocular 125 
conditions, graft selection, AM orientation, surgeon, post-surgical treatment, post-126 
surgical complications, anatomical outcome, epithelial healing time, follow-up, 127 
corneal opacification and visual outcome. Clinically apparent corneal malacia and 128 
corneal infiltration were recorded as either ‘present’ or ‘not present’ at the time of 129 
initial presentation.  ‘Omnigen utilisation’ described whether Omnigen was used as a 130 
standalone material or in combination with another biomaterial, as well as how it was 131 
oriented with respect to the corneal surface: if Omnigen was sutured in place with 132 
the AM epithelium facing up (away from the corneal surface), this was termed a 133 
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‘graft’, if it was sutured in place with the AM epithelium facing down (in contact with 134 
the corneal surface) this was termed a ‘patch’. In cases where Omnigen was used as 135 
a standalone graft, 1-4 layers were used. In cases where the ‘Swiss Roll’ method 136 
was used, this was performed as described by Chan et al.[66] i.e. by rolling the AM 137 
and suturing the rolled tissue into the defect. In eyes where Omnigen was used in 138 
combination with another type of graft, it was either used as a supplementary top 139 
layer graft (epithelium up) or as a ‘patch’ (epithelium down) on top of the other graft. 140 
The other graft material was either porcine urinary bladder submucosa (ACell Vet™; 141 
ACell, Inc. Columbia, MD, USA) or frozen donor cornea. Regardless of utilisation 142 
technique, Omnigen was always fixated with 8/0-9-0 absorbable suture. The 143 
surgeons decided whether to use Omnigen as a patch or graft, depending on 144 
whether it was meant to integrate into the cornea for tectonic support and the 145 
provision of beneficial factors, or as a protective layer providing improved comfort 146 
and healing of the underling graft. Only complications thought to be related to the 147 
initial surgery were noted.  Complications were divided into ‘minor graft 148 
complications’ and ‘graft failures’; ‘minor graft complications’ included any changes 149 
that did not require further medical or surgical intervention. ‘Graft failures’ included 150 
any deterioration that required additional intensive medical management or surgical 151 
intervention. Anatomical outcome was categorised as follows: eyes that ‘healed’, 152 
eyes that ‘healed after intensive medical or surgical intervention’, and eyes that were 153 
‘enucleated’.  ‘Epithelial healing time’, recorded in days, was determined by means 154 
of negative fluorescein uptake. ‘Follow-up time’ (time from presentation until final 155 
examination) was also recorded in days. Corneal neovascularisation was denoted as 156 
‘present’ or ‘absent’ at any point during the follow-up period. The presence or 157 
absence of two features of corneal opacification were noted as per final examination 158 
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records: ‘corneal pigmentation’ and ‘corneal fibrosis’. ‘Visual status’ was determined 159 
at the final post-operative examination and was characterized by the presence or 160 
absence of a menace response, as recorded in contemporaneous clinical notes.   161 
 162 
Data and statistical analysis 163 
Percentages and medians were used to summarise categorical and continuous 164 
variables. Age and epithelial healing time were assessed as continuous variables 165 
and species, breed, brachycephalic status, gender, eye, diagnosis, complicating 166 
factors, concurrent ocular conditions, graft selection, AM orientation, post-surgical 167 
complications, anatomical outcome, corneal opacification and visual outcome were 168 
assessed as nominal variables.  Some nominal variables were analysed by Fischer’s 169 
exact test.  Variables with P<0.05 were considered significant. Statistical analyses 170 
were performed using IBM SPSS software (IBM SPSS Statistics for Macintosh, 171 





A total of 46 eyes (from 45 animals) were included in the study.  This comprised 5/45 177 
(11.1%) cats and 40/45 (88.9%%) dogs.  Brachycephalic breeds were over-178 
represented (37/45; 82.2%).  The most common breed was Pug (14/45; 31.3%), 179 
followed by French Bulldog (8/45; 17.8%), Shih Tzu (8/45; 17.8%), domestic 180 
shorthair cat (4/45; 8.9%), followed by one each (1/45; 2.2%) of the listed breeds: 181 
Chihuahua, British Bulldog, Cavalier King Charles Spaniel, domestic long hair cat, 182 
Jack Russell Terrier, Lhasa Apso, Miniature Schnauzer, Pekingese, Pomeranian and 183 
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Yorkshire Terrier.  The sample population included 4/45 entire females (8.9%), 9/45 184 
(20.0%) spayed females, 9/45 (20.0%) entire males and 23/45 (51.1%) neutered 185 
males. Median age was 4.7 years (interquartile range 6.0 years, range 0.9 years – 186 
13.2 years).  187 
 188 
Ophthalmic examination and diagnostics 189 
Out of 46 total eyes, 22/46 (47.8%) were right eyes and 24/47 (52.2%) were left 190 
eyes.  Forty-four out of forty-five (97.8%) patients were affected unilaterally and 1/45 191 
(2.2%) was affected bilaterally. The most common diagnosis was deep stromal 192 
ulceration (23/46 eyes; 50.0%), followed by corneal perforation (14/46 eyes; 30.4%), 193 
descemetocoele (5/46 eyes; 10.9%), mid-stromal ulceration (2/46 eyes; 4.3%), 194 
corneal sequestrum (1/46 eyes; 2.2%) and corneal laceration (1/46 eyes; 2.2%). 195 
Corneal malacia was detected in 15/46 (32.6%) eyes and corneal infiltration was 196 
present in 26/46 (56.5%) eyes. Evidence of microorganisms was found in corneal 197 
samples from 19/46 (41.3%) cases, by cytology, microbiology and/or histopathology.  198 
Of those 19 cases, cytological findings were reported for 18/19 (94.7%) eyes; 6/18 199 
(33.3%) exhibited cocci or diplococci, 6/18 (33.3%) exhibited rods, 4/18 (22.2%) 200 
exhibited a mixed bacterial population and in the remaining 2/18 (11.1%) samples no 201 
microorganisms were found. Microbiological diagnostics were reported for 8/19 202 
(42.1%) cases and included the identification of Pseudomonas aeruginosa (2/8; 203 
25%), Pasteurella spp. (1/8; 12.5%), Streptococcus canis (1/8; 12.5%), 204 
Staphylococcus pseudointermedius (1/8; 12.5%) and Escherichia coli (1/8; 12.5%); 205 
there was no growth from 4/8 (50%) samples.  Sensitivity testing was performed for 206 
all positive microbiology samples and topical antibacterial treatment was adjusted 207 
accordingly. Corneal histopathology, performed in 1/19 (5.3%) cases, revealed the 208 
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presence of fungal elements (species unidentified). ‘Entropion and euryblepharon’ 209 
was the most common concurrent ocular finding (13/46; 28.3%), followed by 210 
‘keratoconjunctivitis sicca (KCS)’ (5/46; 10.9%), ‘entropion’ (5/46; 10.9%), 211 
‘euryblepharon’ (2/46; 4.3%), ‘entropion and ectopic cilia’ (1/46; 2.2%), ‘entropion 212 
and distichia’ (1/46; 2.2%), ‘eyelid mass and retinal degeneration’ (1/46; 2.2%), 213 
‘ipsilateral cataract’ (1/46; 2.2%), ‘ipsilateral facial nerve paralysis and KCS’ (1/46; 214 
2.2%) and ‘euryblepharon and KCS’ (1/46; 2.2%). There were no concurrent 215 
ophthalmic conditions in 14/46 (30.4%) cases.  216 
 217 
Omnigen utilisation 218 
Cases were allocated to one of three different groups according to how Omnigen 219 
was utilised: Omnigen was used as a standalone graft (epithelium facing up) in 5/46 220 
(10.9%) cases, as a supplementary graft in combination with another biomaterial 221 
(epithelium side facing up) in 29/46 (63.0%) cases and as a ‘patch’ (epithelium facing 222 
down) either on its own or over another graft in 12/46 (26.1%) cases. In those cases 223 
where Omnigen was used as an adjunctive graft or as a patch over a graft, the 224 
additional graft materials comprised porcine urinary bladder submucosa (ACell Vet) 225 
in 33/46 (71.7%) cases and frozen donor cornea in 7/46 (15.2%) cases. Omnigen 226 
patches were not removed but were left to spontaneously slough from the ocular 227 
surface. The date of sloughing was recorded in 2/12 cases as 1 and 3 days, 228 
respectively, following surgery. In 3/12 cases the presence of the patch was 229 
described at 2, 2 and 33 days, respectively, following surgery.  In the remaining 7/12 230 
cases, neither date of sloughing nor post-operative presence of the patch was 231 
recorded.   232 
 233 
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Post-surgical treatment  234 
Post-surgical treatment, which varied according to clinician and patient factors, 235 
included the use of topical chloramphenicol 0.5% w/v (generic form), topical 236 
ofloxacin (Exocin®, Allergan, Dublin, Ireland), topical ciprofloxacin (Ciloxan®, 237 
Novartis, Surrey, U.K.), topical atropine (Minims atropine sulphate 1%®, Bausch & 238 
Lomb, Surrey, U.K.), topical serum (prepared in-house from canine blood donors), 239 
topical carmellose sodium (Celluvisc® 1% w/v, Allergan, Westport, Ireland), topical 240 
ciclosporin (Optimmune® 2mg/g ointment, MSD Animal Health, Milton Keynes, 241 
U.K.), systemic meloxicam (Metacam® 1.5mg/ml, Boehringer Ingelheim Animal 242 
Health Ltd., Bracknell, U.K.), systemic carprofen 4mg/kg once daily (Rimadyl®, 243 
Pfizer, Tadworth, Surrey), systemic firocoxib (Previcox®, Boehringer Ingelheim 244 
Animal Health Ltd., Bracknell, U.K.), systemic cefalexin (Rilexine®, Virbac, Bury St 245 
Edmunds, U.K.) and systemic doxycycline (Ronaxan®, Boehringer Ingelheim Animal 246 
Health Ltd., Bracknell, U.K.).  247 
 248 
Epithelial healing time and follow-up time 249 
Median epithelial healing time was 19.0 days (interquartile range 17 days, range 8 – 250 
67 days).  Median follow-up time was 84 days (interquartile range 256 days, range 2 251 
– 1046 days).  252 
 253 
Complications, outcome and corneal opacification 254 
Complications, outcome and corneal opacification according to Omnigen utilisation 255 
and respective outcome variables are summarised in Table 1. Thirty-one out of 256 
thirty-three (93.9%) eyes were visual at the final examination; this figure excludes 257 
three eyes which were enucleated and 10 cases for which the visual status was not 258 
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recorded. The remaining 2/46 cases that were not visual were blind due to extensive 259 
corneal neovascularisation (1/46; 2.2%) and retinal degeneration (1/46; 2.2%),  260 
Successful anatomical healing (including eyes that required additional intervention) 261 
occurred in 43/46 eyes (93.5%). Graft failure lead to enucleation in 3/46 (6.5%) 262 
cases, due to persistent malacia in 2/46 (4.3%) cases where Omnigen was used as 263 
a supplementary graft and corneal perforation under the graft in 1/46 (2.2%) case 264 
where Omnigen was used as a standalone graft. Eyes that were enucleated (3/46; 265 
6.5%) were excluded from the corneal neovascularisation, pigmentation, fibrosis and 266 
visual outcome data.   Minor graft complications (10/46; 21.7%) included partial graft 267 
retraction (4/46; 8.7%), corneal degeneration adjacent to the graft (2/46; 4.3%), 268 
anterior synechiae (2/46; 4.3%), secondary glaucoma due to extensive anterior 269 
synechiae (1/46; 2.2%) and development of an inclusion cyst within the graft site 270 
(1/46;2.2%)).  Graft failures (10/46; 21.7%) were attributable to complete graft 271 
dehiscence (3/46; 6.5%), progressive malacia (3/46; 6.5%), perforation under the 272 
graft (3/46; 6.5%) and persistent aqueous leakage (1/46; 2.2%). Fisher’s exact test 273 
was performed on some categorical variables; results are summarised in Table 2.  274 
Significant associations were found between brachycephalic status and corneal 275 
pigmentation and between complications and anatomical outcome; brachycephalic 276 
dogs were more likely to develop corneal pigmentation (P=0.002) and eyes with graft 277 




Amniotic membrane is used in humans and in veterinary species for the treatment of 282 
a wide range of ocular surface disorders, including the treatment of ocular burns, 283 
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severe chemical and thermal eye injuries, refractory neurotrophic ulcers, deep 284 
corneal ulcers, partial limbal stem cell deficiency, persistent epithelial defect, 285 
pterygium, canine dermoids, canine complicated ulcers, equine keratomalacia, 286 
equine immune-mediated keratitis and feline sequestrum 287 
[49,60,62,63,67,73,75,76,78,79,105]. In this study, a novel low-temperature vacuum-288 
dehydrated AM, Omnigen, was applied in the primary surgical repair of 46 eyes from 289 
45 cats and dogs with corneal ulceration.  290 
 291 
The varied utilisation of Omnigen in this study demonstrated satisfactory overall 292 
anatomical and visual outcome (93.5% and 93.9% respectively). The present study 293 
demonstrates the use of Omnigen in several different ways; as a standalone graft, as 294 
a supplementary graft and as a patch. In those cases where Omnigen was used as a 295 
standalone graft, the anatomical and visual outcomes were 80% and 100% 296 
respectively; these results are comparable to previous studies on the use of fresh 297 
and cryopreserved AM for treatment of corneal defects in veterinary species, which 298 
demonstrated satisfactory to good overall outcome (71.4% - 100%) [63-299 
65,72,79,84,85,105,106] The clinical use of Omnigen in combination with corneal 300 
cross-linking was briefly described in a recent veterinary study[104]; this study 301 
reported good anatomical and visual outcomes of 84.6% (11/13) and 76.9% (10/13) 302 
cases, respectively.  In the present study, the subset of cases where Omnigen was 303 
used as a standalone graft was very small (5/46) which is a limitation. For those 304 
cases where Omnigen was used as a supplementary graft with either ACell Vet or 305 
frozen donor cornea, the anatomical and visual outcomes were 93.1% and 90.5%, 306 
respectively. Similar results were reported for the use of ACell Vet alone (73.3% – 307 
100% good outcome)[29-32] and frozen donor cornea alone (95% - 100% good 308 
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visual outcome, 86% good anatomical outcome)[11,107]; however, these studies do 309 
not provide a perfect comparison as they describe the sole use of these biomaterials 310 
without supplementary Omnigen or other AM.  311 
 312 
The prevalence of post-surgical complications in the present study was reasonably 313 
high, with a total of 10/46 (21.7%) eyes experiencing minor complications and 10/46 314 
(21.7%) eyes exhibiting complete graft failure. Interestingly, corneal degeneration 315 
adjacent to the graft was reported a minor complication in 2/46 (4.3%) eyes; in both 316 
cases this had the clinical appearance of corneal lipid and/or calcium deposition. 317 
Corneal calcification following AM graft has been reported in 12.8% of cases in the 318 
human literature[108], but has not previously been described in veterinary patients. A 319 
common risk factor for corneal calcification in the cited study included the post-320 
operative use of phosphate containing eyedrops; however, these were not 321 
prescribed for the two cases in the present study. Graft failures occurred 322 
predominantly due to complete graft dehiscence, progressive malacia and 323 
perforations under the graft. The highest graft failure rate occurred in the group 324 
where Omnigen was utilised as a supplementary graft and slightly lower in the 325 
groups where Omnigen was used as a standalone graft (20.0%) or as a patch 326 
(8.3%). The reasons for the high complication rate within this sample population are 327 
difficult to elucidate, due in part to the combination of graft materials used and the 328 
relatively small sample size.  The authors feel that an important factor to consider is 329 
the complicated nature of the corneal defects included in this study.  According to the 330 
surgeons involved, Omnigen was typically selected for use in ‘high-risk’ or 331 
‘catastrophic’ ulcers; this would have led to an inevitable population bias.   332 
 333 
 15 
The occurrence of corneal neovascularisation was high (100%) which was 334 
somewhat unexpected given the purported anti-angiogenic and anti-inflammatory 335 
effects of amnion. This could perhaps be attributable to a degree of graft rejection, 336 
as has been speculated upon in previous studies on the use of xenografts in 337 
veterinary species[64,72]. If so, this could have implications for our understanding of 338 
immunogenicity of amniotic xenotransplants in the cornea[59]. Alternatively, it may 339 
be that the initial neovascularisation is a transient response; longer-term studies 340 
would be helpful in determining if this is the case.  341 
 342 
Corneal opacification is a parameter of interest when considering the use of AM, due 343 
to previous reports of anti-fibroblastic and anti-inflammatory properties [44,48].  In 344 
the present study, the overall occurrence of corneal pigmentation and fibrosis at final 345 
examination was reasonably high, at 55.8% and 100% respectively. Specifically, in 346 
the group where Omnigen was used as a standalone graft, the pigmentation rate 347 
was lower (20%) although the fibrosis rate was still high (100%). This is comparable 348 
to a recent study by Plummer et al [85], which revealed some degree of ‘corneal 349 
scarring’ in 100% of equine patients that underwent amnion transplantation for ocular 350 
surface reconstruction. Assessment of corneal opacification was limited in the 351 
present study, due to lack of an objective scale of opacification in the 352 
contemporaneous clinical notes, and the variation in follow-up time. Here, again, 353 
longer-term studies would be helpful in determining how the use of Omnigen affects 354 
the final corneal opacification outcome.  355 
 356 
Statistical analysis in general was limited in the present study, due to the nature of 357 
the study.  As a retrospective study with a relatively small sample size, much of the 358 
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data was not suitable for extensive analysis. Statistically significant findings were 359 
limited to the following: brachycephalic dogs were more likely to develop corneal 360 
pigmentation and those eyes with graft failures were more likely to be enucleated.  361 
The propensity of brachycephalics to corneal pigmentation post-surgery is a 362 
generally accepted anecdotal finding, and the correlation between graft failure and 363 
enucleation makes biological sense; these findings are therefore easy to accept.   364 
 365 
Limitations of the present study were as expected in an observational retrospective 366 
of study small sample size, including the limited ability to measure key findings e.g. 367 
visual status (limited to the relatively crude assessment of absent or present menace 368 
response), epithelial healing time (result of fluorescein testing was not always noted 369 
in the clinical record), corneal opacification (limited to presence/absence of corneal 370 
pigmentation and fibrosis, where an objective corneal clarity score or other grading 371 
scheme would have been more helpful), time until sloughing of the patch (not 372 
recorded for most cases), significant biases (selection of ‘high-risk’ cases for 373 
Omnigen use), corneal ulcer size (not recorded in clinical notes) different surgeons 374 
and surgical techniques, disparity in post-operative treatments, and variation in 375 




This study describes the successful use of Omnigen for the treatment of corneal 380 
ulceration in 46 eyes from 45 cats and dogs, using a variety of methods, resulting in 381 
satisfactory anatomical and visual outcomes in the majority of cases.  Future clinical 382 
research comprising prospective studies designed to reduce the limitations 383 
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encountered here would undoubtedly provide more accurate information on the 384 
clinical use and potential benefits of Omnigen, particularly its use as a standalone 385 
graft and in comparison to other forms of amnion.    386 
 387 
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  Complications Corneal 
pigmentation 
Anatomical outcome Visual outcome 
Predictor 
variables 
Brachycephaly 0.825 0.002 0.179 0.549 
Gender 0.238 0.126 1.000 0.818 
Eye affected (right vs. 
left) 
0.798 0.760 0.800 1.000 
Diagnosis 0.503 0.122 0.648 0.374 
Corneal malacia 0.889 0.743 0.170 1.000 
Corneal infiltration 0.449 0.547 0.486 0.136 
Omnigen® utilisation 0.803 0.370 0.711 0.152 
Complications - 0.532 <0.001 0.641 
Corneal pigmentation 0.532 - 0.517 1.000 
Table 2. Results of Fischer’s exact test expressed as P-values; values in bold are statistically significant (P<0.05). 
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